IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 976-1000 out of 1364.

<< < 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 > >>

Public Release: 27-Feb-2015
Nature Protocols
New approach to assessing effectiveness of anti-cancer drugs
Manchester scientists have a developed a new method to monitor the effect of anti-cancer drugs on very rare leukaemia stem cells. The approach potentially allows doctors to screen patients and personalise their treatment.

Contact: Jamie Brown
Jamie.brown@manchester.ac.uk
44-016-127-58383
University of Manchester

Public Release: 27-Feb-2015
JAMA Oncology
Researchers detail reasons for ibrutinib therapy discontinuation in CLL
About 10 percent of patients with chronic lymphocytic leukemia discontinued therapy with the Bruton tyrosine kinase inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study published online in JAMA Oncology by scientists at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

Contact: Amanda J. Harper
amanda.harper2@osumc.edu
614-685-5420
Ohio State University Wexner Medical Center

Public Release: 27-Feb-2015
Journal of Cell Biology
Breakthrough in understanding how cancer cells metastasize
A protein commonly found in human cells could be an important switch that activates cancer cell metastasis, according to a new study by researchers at the Montreal Neurological Institute and Hospital -- The Neuro at McGill University and the MUHC. The finding focuses attention on a biological mechanism that until now was largely overlooked. The discovery of the protein's effect significantly expands our understanding of epithelial cancers such as breast and lung cancer.

Contact: Anita Kar
anita.kar@mcgill.ca
514-398-3376
McGill University

Public Release: 27-Feb-2015
Modern Pathology
New breast cancer test links immune 'hotspots' to better survival
Scientists have developed a new test which can predict the survival chances of women with breast cancer by analyzing images of 'hotspots' where there has been a fierce immune reaction to a tumor. Researchers used statistical software previously used in criminology studies of crime hotspots to track the extent to which the immune system was homing in and attacking breast cancer cells.
Engineering and Physical Sciences Research Council, The Institute of Cancer Research, London

Contact: Claire Hastings
chastings@icr.ac.uk
020-715-35380
Institute of Cancer Research

Public Release: 27-Feb-2015
Genitourinary Cancers Symposium
Mount Sinai researchers find chemotherapy after bladder cancer surgery improved survival
Patients that received chemotherapy after bladder cancer surgery demonstrated an approximately 30 percent lower risk of death than those that underwent surgery alone.

Contact: Lucia Lee
lucia.lee@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 27-Feb-2015
Nature Reviews Clinical Oncology
Anderson Algorithm increases surgical success with advanced ovarian cancer
A surgical algorithm developed and implemented by ovarian cancer specialists at The University of Texas MD Anderson Cancer Center dramatically increases the frequency of complete removal of all visible tumor -- a milestone strongly tied to improved survival.

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center

Public Release: 26-Feb-2015
JAMA Oncology
Blood samples as surrogates for tumor biopsies in patients with lung cancer
A study examined the feasibility of using circulating free DNA from blood samples of patients with advanced non-small-cell lung cancer as a surrogate for tumor biopsies to determine tumor-causing epidermal growth factor receptor mutations and then correlate that with expected patient outcomes, according to a study published online by JAMA Oncology.

Contact: Rafael Rosell, M.D.
rrosell@iconcologia.net
The JAMA Network Journals

Public Release: 26-Feb-2015
European Journal of Cancer
Real-life study for YONDELIS® in sarcoma show comparable or better efficacy than clinical trials
The study reinforces the efficacy of YONDELIS® (trabectedin) in multiple types of soft-tissue sarcoma and supports that long-term treatment delays disease progression. Even in heavily pretreated patients, the efficacy outcomes of the drug were similar or improved compared to historical controls.
French NetSARC Network, EuroSarc

Contact: Carolina Pola
cpola@pharmamar.com
34-608-933-677
Pharmamar

Public Release: 26-Feb-2015
JAMA Oncology
Patient perceptions of physician compassion measured
Cancer patients perceived a higher level of compassion and preferred physicians when they provided a more optimistic message in a clinical trial that used videos with doctors portrayed by actors, according to a study published online by JAMA Oncology.

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
The JAMA Network Journals

Public Release: 26-Feb-2015
JAMA Oncology
Reasons for ibrutinib therapy discontinuation in patients with chronic lymphocytic leukemia
About 10 percent of patients with chronic lymphocytic leukemia discontinued therapy with the Bruton tyrosine kinase inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study published online by JAMA Oncology.

Contact: Amanda J. Harper
amanda.harper2@osumc.edu
614-685-5420
The JAMA Network Journals

Public Release: 26-Feb-2015
Cell
Novel precision medicine tool could help personalize cancer treatments
A new laboratory test accurately predicted which of many drug treatments would most effectively kill cancer cells in the laboratory and in the clinic. If validated in ongoing clinical trials, the test could be ready to inform patient care in about two years.
National Institutes of Health

Contact: Teresa M Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute

Public Release: 26-Feb-2015
Journal of the National Cancer Institute
Statin use associated with reduced risk of liver cancer among those in the UK
In a nested-case control study of individuals living in the UK, a part of the world with a relatively low incidence of liver cancer, statin use is associated with a decreased risk of liver cancer, according to a new study published Feb. 26 in the JNCI: Journal of the National Cancer Institute.

Contact: Zachary Rathner
Zachary.Rathner@oup.com
919-677-2697
Oxford University Press USA

Public Release: 26-Feb-2015
Journal of the Royal Society of Medicine
Global health experts call into question sub-Saharan cancer data
Global health experts believe the current data on cancer prevalence, incidence and mortality in sub-Saharan Africa -- which determines how billions of pounds of international development money is spent -- are weak and could mean vital funds are being deflected from other priorities. These include diarrheal and waterborne diseases, malnutrition, sanitation and the need to strengthen health systems.

Contact: Charli Scouller
c.scouller@qmul.ac.uk
07-709-825-741
Queen Mary, University of London

Public Release: 26-Feb-2015
Cell
Growth signal can influence cancer cells' vulnerability to drugs, study suggests
Some cells within a tumor may succumb to anti-cancer drugs, while others survive to bring back the cancer. Research at Rockefeller University explains one mechanism behind this variable vulnerability: exposure to TGF-beta, a signal that restricts growth in healthy tissue.

Contact: Wynne Parry
wparry@rockefeller.edu
212-327-7789
Rockefeller University

Public Release: 26-Feb-2015
Cell Reports
Leukemia-associated mutations almost inevitable as we age
It's almost inevitable that we'll develop mutations associated with leukemia as we age, according to research today in Cell Reports. These mutations are more common than previously thought and their numbers increase significantly with age. Scientists analyzed DNA mutations present in minute concentrations of blood from people without leukemia. Approximately 20 percent of people aged 50-60 and more than 70 percent over 90 are thought to have cells with leukemia-associated mutations.
Wellcome Trust Clinician Scientist Fellowship, Wellcome Trust Sanger Institute, Wellcome Trust Senior Fellowship in Clinical Science, Leukaemia Lymphoma Research, Kay Kendal Leukaemia Fund, Spanish Ministerio de Economía y Competitividad

Contact: Mary Clarke
press.office@sanger.ac.uk
01-223-492-368
Wellcome Trust Sanger Institute

Public Release: 26-Feb-2015
New England Surgical Society 95th Annual Meeting
Journal of American College of Surgeons
Chemo before breast cancer operation increases likelihood of breast-preserving procedure
Patients with larger malignant tumors of the breast who undergo chemotherapy before a breast cancer operation are more likely to opt for a breast-preserving procedure and forgo a mastectomy (surgical removal of the breast), according to a new study published online as an 'article in press' in the Journal of the American College of Surgeons. The study will appear in a print edition of the Journal this spring.

Contact: Sally Garneski
pressinquiry@facs.org
312-202-5409
American College of Surgeons

Public Release: 26-Feb-2015
Journal of Thoracic Oncology
Online education tool helps bridge gaps in therapeutic decision-making for advanced NSCLC
A new interactive online tool helps educate practicing oncologists worldwide with therapeutic decision-making for advanced non-small cell lung cancer based on a patient's molecular and clinical characteristics by providing feedback from an expert panel.

Contact: Murry Wynes
Murry.Wynes@iaslc.org
720-325-2945
International Association for the Study of Lung Cancer

Public Release: 26-Feb-2015
PLOS ONE
Cancer screening concerns
Adults with intellectual and developmental disabilities are much less likely to be screened for colorectal cancer, research shows.

Contact: Rosie Hales
rosie.hales@queensu.ca
613-533-6000 x77513
Queen's University

Public Release: 26-Feb-2015
BMC Medicine
The numbers are in: 1.8 millions Australian smokers likely to die from their habit
The first large-scale, direct evidence on smoking and mortality in Australia shows up to 1.8 million of our 2.7 million smokers are likely to die from their habit if they continue to smoke, losing on average 10 years of life expectancy.

Contact: Anne Rahilly
arahilly@unimelb.edu.au
61-390-355-380
University of Melbourne

Public Release: 26-Feb-2015
Journal of Biological Chemistry
Moffitt researchers identify protein pathway involved in brain tumor stem cell growth
Glioblastomas are a highly aggressive type of brain tumor, with few effective treatment options. Moffitt Cancer Center researchers are one step closer to understanding glioblastoma development following the identification of a key protein signaling pathway involved in brain tumor stem cell growth and survival. Brain tumor stem cells are believed to play an important role in glioblastoma development and may be possible therapeutic targets.
The V Foundation for Cancer Research, Moffitt Cancer Center Foundation.

Contact: Kim Polacek
Kim.Polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 26-Feb-2015
American Journal of Roentgenology
Ultrasound lags behind MRI for supplemental breast cancer screening
Although supplemental screening via ultrasound is unaffected by breast density, is not associated with ionizing radiation, and does not require IV contrast material, acceptance of this modality has lagged.

Contact: Lissa D. Hurwitz
lhurwitz@arrs.org
703-858-4332
American Roentgen Ray Society

Public Release: 26-Feb-2015
Proceedings of the National Academy of Sciences
Discovery about beliefs could prove useful in addiction treatment, researchers say
Virginia Tech Carilion Research Institute scientists have discovered that beliefs can regulate the effects of nicotine on the human brain.

Contact: Paula Brewer Byron
paulabyron@vt.edu
540-526-2027
Virginia Tech

Public Release: 26-Feb-2015
Oncotarget
IU researchers identify pancreatic cancer patients who benefit from personalized treatment
Cancer researchers at Indiana University report that about 15 percent of people with pancreatic cancer may benefit from therapy targeting a newly identified gene signature.
NIH/National Cancer Institute

Contact: Michael Schug
maschug@iupui.edu
317-278-0953
Indiana University

Public Release: 26-Feb-2015
British Journal of Cancer
Urine test could lead to better treatment of bladder cancer
Researchers at the University of Birmingham believe that a simple urine test could help to guide clinicians in the treatment of bladder cancer patients.
Cancer Research UK, University of Birmingham, Birmingham/Black Country/West Midlands North and South Comprehensive Local Research Networks, University of Birmingham

Contact: Luke Harrison
l.harrison.1@bham.ac.uk
University of Birmingham

Public Release: 26-Feb-2015
Current Biology
Skeleton of cells controls cell multiplication
A research team from Instituto Gulbenkian de Ciencia, led by Florence Janody, in collaboration with Nicolas Tapon from London Research Institute, discovered that the cell's skeleton can trigger the multiplication of cells through the action of proteins that control cellular rigidity. During this process genes that promote cancer -- oncogenes -- become activated, leading to tumor formation in living organisms. This study was published in the latest edition of the scientific journal Current Biology.
Fundacao para a Ciencia e a Tecnologia, Cancer Research UK

Contact: Ana Mena
anamena@igc.gulbenkian.pt
351-214-407-959
Instituto Gulbenkian de Ciencia

Showing releases 976-1000 out of 1364.

<< < 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 > >>

  Search News Releases

     

 

EurekAlert!